However, only 5.2 % of US adults with ASCVD and recommended for add-on lipid-lowering therapy were taking ezetimibe or a PCSK9 inhibitor, and the percentage of US adults taking ezetimibe or a PCSK9 inhibitor was low in all subgroups investigated including those taking and not taking a statin. This evidence concerns the gene PCSK9 and atherosclerosis.